JP2022524018A5 - - Google Patents
Info
- Publication number
- JP2022524018A5 JP2022524018A5 JP2021552750A JP2021552750A JP2022524018A5 JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5 JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- formula
- sequence
- formulas
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025176328A JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814669P | 2019-03-06 | 2019-03-06 | |
| US62/814,669 | 2019-03-06 | ||
| US201962899504P | 2019-09-12 | 2019-09-12 | |
| US62/899,504 | 2019-09-12 | ||
| US202062962332P | 2020-01-17 | 2020-01-17 | |
| US62/962,332 | 2020-01-17 | ||
| PCT/US2020/021498 WO2020181235A1 (en) | 2019-03-06 | 2020-03-06 | Il-10 variant molecules and methods of treating inflammatory disease and oncology |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176328A Division JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524018A JP2022524018A (ja) | 2022-04-27 |
| JP2022524018A5 true JP2022524018A5 (cg-RX-API-DMAC7.html) | 2023-04-26 |
Family
ID=72334859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552750A Withdrawn JP2022524018A (ja) | 2019-03-06 | 2020-03-06 | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
| JP2025176328A Pending JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176328A Pending JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (9) | US10858412B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3934681A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022524018A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210139312A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114072164A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132385A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020181235A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10017739B2 (en) * | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Il13を含む融合タンパク質 |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| CN116322785A (zh) | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| CN112898436A (zh) * | 2020-10-23 | 2021-06-04 | 广州医科大学附属肿瘤医院 | 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用 |
| KR102792982B1 (ko) * | 2021-05-28 | 2025-04-14 | 한양대학교 산학협력단 | 세포투과성 펩티드 및 이의 용도 |
| EP4414381A4 (en) * | 2021-11-02 | 2025-01-22 | Guangdong Fapon Biopharma Inc. | MONOMERIC FUSION PROTEIN OF IL-10 AND ITS USE |
| KR20240156653A (ko) * | 2021-12-13 | 2024-10-30 | 데카 바이오사이언시즈, 인크. | 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질 |
| JP2024546999A (ja) * | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー |
| AU2023225954A1 (en) | 2022-02-22 | 2024-09-05 | Deka Biosciences, Inc. | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins |
| CN114632156B (zh) * | 2022-05-17 | 2022-08-16 | 中国人民解放军军事科学院军事医学研究院 | Tim-3在预防、治疗或减轻疼痛中的应用 |
| US20260174822A1 (en) * | 2022-11-02 | 2026-06-25 | Shattuck Labs, Inc. | Fusion proteins for the treatment of nonalcoholic steatohepatitis |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| IL328577A (en) * | 2023-11-24 | 2026-07-01 | Medpacto Inc | Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use |
| CN121108363A (zh) * | 2024-06-12 | 2025-12-12 | 广东菲鹏制药股份有限公司 | 一种融合蛋白及其用途 |
| CN119613546B (zh) * | 2025-02-10 | 2025-05-13 | 细胞生态海河实验室 | Il-10抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009536170A (ja) * | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| ES2536772T3 (es) * | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| EP2209805B1 (en) * | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| WO2012045334A1 (en) * | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| EP2903629B1 (en) * | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
| BR112016016658A2 (pt) * | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) * | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2017091611A1 (en) * | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| US10144768B2 (en) * | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
-
2020
- 2020-03-06 CN CN202080033670.7A patent/CN114072164A/zh active Pending
- 2020-03-06 JP JP2021552750A patent/JP2022524018A/ja not_active Withdrawn
- 2020-03-06 CN CN202511790818.2A patent/CN121652287A/zh active Pending
- 2020-03-06 EP EP20765677.8A patent/EP3934681A4/en active Pending
- 2020-03-06 WO PCT/US2020/021498 patent/WO2020181235A1/en not_active Ceased
- 2020-03-06 CA CA3132385A patent/CA3132385A1/en active Pending
- 2020-03-06 KR KR1020217032047A patent/KR20210139312A/ko active Pending
- 2020-03-06 US US16/811,718 patent/US10858412B2/en active Active
- 2020-08-24 US US17/001,264 patent/US10975133B2/en active Active
- 2020-08-25 US US17/002,537 patent/US20210040168A1/en not_active Abandoned
- 2020-08-25 US US17/002,531 patent/US10981965B2/en active Active
- 2020-08-25 US US17/002,388 patent/US10975134B2/en active Active
- 2020-09-04 US US17/012,841 patent/US10981966B2/en active Active
-
2021
- 2021-05-17 US US17/322,394 patent/US20220106373A1/en not_active Abandoned
-
2024
- 2024-05-07 US US18/657,437 patent/US20240294591A1/en active Pending
-
2025
- 2025-10-20 JP JP2025176328A patent/JP2026016505A/ja active Pending
- 2025-11-14 US US19/390,302 patent/US20260125435A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534847A5 (cg-RX-API-DMAC7.html) | ||
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| Both et al. | Monoclonal antibodies for prophylactic and therapeutic use against viral infections | |
| JP2024546938A5 (cg-RX-API-DMAC7.html) | ||
| US9499619B2 (en) | Polyclonal bispecific antibody compositions and method of use | |
| JP2020036595A5 (cg-RX-API-DMAC7.html) | ||
| JP7164528B2 (ja) | Pd-1に特異的に結合する可能な抗体及びその機能的断片 | |
| US20110275123A1 (en) | Compositions and methods for generating antibodies | |
| JP2025060802A5 (cg-RX-API-DMAC7.html) | ||
| JP2008543774A5 (cg-RX-API-DMAC7.html) | ||
| JP2021516976A5 (cg-RX-API-DMAC7.html) | ||
| IL313525A (en) | Dual cytokine fusion proteins containing multisubunit cytokines | |
| JP2022512915A5 (cg-RX-API-DMAC7.html) | ||
| Roselli et al. | CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al. | |
| JP2020522254A (ja) | 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用 | |
| JP2022033734A (ja) | グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択 | |
| JP2024537804A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527952A5 (cg-RX-API-DMAC7.html) | ||
| RU2016126488A (ru) | Иммунотерапия рака | |
| JP2025508882A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518200A (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| JP2022527994A (ja) | 三重特異性結合性タンパク質、方法、およびその使用 | |
| JP2024546999A5 (cg-RX-API-DMAC7.html) | ||
| JP2023550419A5 (cg-RX-API-DMAC7.html) |